September 29, 2016 – The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis. The report, as well as accompanying draft voting questions, will be open to public comment for three weeks.
ICER is committed to engaging with all stakeholders in a thorough and transparent manner. Before completing this Draft Evidence Report, ICER reached out to key stakeholders, including patient groups, clinical experts, and the manufacturers of the drugs under review to engage them in the process. ICER also opened a Draft Scoping Document to public comment for a three-week period. The current draft report incorporates input received from patients, clinicians, manufacturers, and other stakeholders through each of these opportunities for engagement.
The Draft Evidence Report, as well as the accompanying voting questions, will be open to public comment until October 20, 2016 at 5PM ET. All stakeholders are invited to submit formal comments by email to email@example.com. Guidelines for submitting public comments, including formatting specifications, are available on the ICER website. ICER will review all comments received and incorporate any needed changes in the Evidence Report that will be posted on or about November 4, 2016. All comments will be posted publicly along with the Evidence Report.
The Evidence Report, including value-based price benchmarks for the treatments under review, will be the subject of a public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) on November 18, 2016 in Boston, MA. The independent Council will vote on key questions raised in the reports, and a policy roundtable will discuss recommendations to apply the evidence to policy and practice.
During the public meeting, there will be a limited amount of time available for interested stakeholders to make an oral comment on the report. Beginning today, requests to submit oral comment are being accepted on a rolling basis. All requests must be emailed to firstname.lastname@example.org by 5PM on October 20, 2016. For more information about registering for oral comment, please visit our website.
Registration to attend the meeting is now open.
More information on our methods for public engagement can be found here.